Cargando…
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells
BACKGROUND: Components of the microenvironment such as bone marrow stromal cells (BMSCs) are well known to support multiple myeloma (MM) disease progression and resistance to chemotherapy including the proteasome inhibitor bortezomib. However, functional distinctions between BMSCs in MM patients and...
Autores principales: | Markovina, Stephanie, Callander, Natalie S, O'Connor, Shelby L, Xu, Guangwu, Shi, Yufang, Leith, Catherine P, Kim, KyungMann, Trivedi, Parul, Kim, Jaehyup, Hematti, Peiman, Miyamoto, Shigeki |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095250/ https://www.ncbi.nlm.nih.gov/pubmed/20604947 http://dx.doi.org/10.1186/1476-4598-9-176 |
Ejemplares similares
-
Acetyl-l-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network
por: Callander, Natalie, et al.
Publicado: (2014) -
Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009) -
A feline case of multiple myeloma treated with bortezomib
por: Tani, Hiroyuki, et al.
Publicado: (2022) -
Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006) -
Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma
por: Yang, David T, et al.
Publicado: (2008)